The novel immunotherapy combination of epacadostat plus pembrolizumab shows promising clinical activity in advanced melanoma patients.
Expression of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) is associated with poor glioblastoma outcomes.
HLA-A2-positive glioblastoma patients experienced more frequent immune responses to the dendritic-cell immunotherapy IDT-107, responses that may be associated with improved survival.
Early results from an ongoing trial suggest that pembrolizumab has promising activity in untreated melanoma patients with brain metastases.
Nivolumab alone or in combination with ipilimumab are promising treatment options for patients with mucosal melanoma, according to a new study.
The FDA approved the proteasome inhibitor ixazomib, in combination with lenalidomide and dexamethasone, to be used as a second-line treatment in multiple myeloma.
Dual HER2 blockade with trastuzumab and lapatinib was no better than trastuzumab alone in producing pathologic complete responses in metastatic HER2-positive breast cancer patients in the neoadjuvant setting, according to a new study.
On November 16, 2015, the US Food and Drug Administration (FDA) approved daratumumab (Darzalex) to treat patients with multiple myeloma who have received at least three prior treatments.
The FDA granted accelerated approval to osimertinib (Tagrisso), previously known as AZD9291, for treatment of advanced non-small-cell lung cancer (NSCLC) with the EGFR mutation T790M.
The FDA has approved the MEK inhibitor cobimetinib in combination with the BRAF inhibitor vemurafenib for the treatment of advanced metastatic or unresectable BRAF-mutated melanoma.